Brendan Luu Net Worth

The estimated Net Worth of Brendan Luu is at least 463 千$ dollars as of 5 December 2023. Mr Luu owns over 2,125 units of Enanta Pharmaceuticals Inc stock worth over 442,301$ and over the last 4 years he sold ENTA stock worth over 20,464$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Luu ENTA stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Enanta Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,125 units of ENTA stock worth 20,464$ on 5 December 2023.

The largest trade he's ever made was selling 2,125 units of Enanta Pharmaceuticals Inc stock on 5 December 2023 worth over 20,464$. On average, Mr trades about 213 units every 0 days since 2021. As of 5 December 2023 he still owns at least 36,736 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Mr Luu stock trades at the bottom of the page.

Mr. Brendan Luu biography

Brendan Luu is the Sr. VP of Bus. Devel. at Enanta Pharmaceuticals Inc.

What's Mr Luu's mailing address?

Brendan's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over 72,640,961$ worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth 5,071,651$ . The most active insiders traders include Jay R. Luly、V Life Science Ventures Gmb...、Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of 285,155$. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth 190,762$.

What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Complete history of Mr Luu stock trades at Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jay Luly,
  President, Chief Executive Officer, Director
• Yat Sun Or,
  Senior Vice President - Research & Development, Chief Scientific Officer
• Nathalie Adda,
  Senior Vice President and Chief Medical Officer
• Paul Mellett,
  Chief Financial Officer, Senior Vice President - Finance & Administration
• Nathaniel Gardiner,
  Senior Vice President, General Counsel
• Dr. Jay R. Luly,
  Pres, CEO & Director
• Dr. Yat Sun Or,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Nathalie Adda,
  Sr. VP & Chief Medical Officer
• Nathaniel S. Gardiner J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Paul J. Mellett Jr.,
  Sr. VP of Fin. & Admin. and CFO
• Bruce Carter,
  Independent Non-Executive Chairman of the Board
• Terry Vance,
  Independent Director
• George Golumbeski,
  Independent Director
• Lesley Russell,
  Independent Director
• Kristine Peterson,
  Independent Director
• Mark Foletta,
  Independent Director
• Carol Miceli,
  Director, Investor Relations
• Brendan Luu,
  Sr. VP of Bus. Devel.
• Tara Lynn Kieffer Ph.D.,
  Sr. VP of New Product Strategy & Devel.
• Jennifer Viera,
  Sr. Director of Investor Relations & Corp. Communications
• Ernst Guenter Afting,
  Director
• Tim Ocain,
  Senior Vice President
• Stephen Jr. Buckley,
  Director
• V Life Science Ventures Gmb...,
  
• V Life Science Ventures Gmb...,
  
• Helmut Schuhsler,
  Director
• David Poorvin,
  Director
• Capital Granite, L.P.M Rna ...,
  
• Marc E. Goldberg,
  Director
• Gregory L. Verdine,
  Director
• & Co Ltd Shionogi,
  10% owner
• Yujiro S Hata,
  Director
• Brendan Luu,
  Chief Business Officer
• Scott T. Rottinghaus,
  Chief Medical Officer
• Tara Lynn Kieffer,
  Chief Product Strategy Officer
• Matthew Paul Kowalsky,
  Chief Legal Officer